Shattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results

Shattuck Labs (NASDAQ:STTK) released its quarterly earnings results on Thursday. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08, Briefing.com reports. Shattuck Labs had a negative net margin of 5,268.44% and a negative return on equity of 63.08%. The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.30 million. The firm’s quarterly revenue was up 2200.0% compared to the same quarter last year.

Shattuck Labs Price Performance

STTK traded down $0.32 during trading on Friday, hitting $10.78. The company’s stock had a trading volume of 255,662 shares, compared to its average volume of 357,197. Shattuck Labs has a twelve month low of $1.33 and a twelve month high of $11.62. The stock has a market cap of $512.59 million, a PE ratio of -5.43 and a beta of 1.98. The firm’s 50 day moving average price is $9.38 and its 200-day moving average price is $6.88.

Insider Transactions at Shattuck Labs

In related news, insider Stephen Stout sold 16,004 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $10.53, for a total value of $168,522.12. Following the completion of the transaction, the insider now directly owns 74,437 shares in the company, valued at $783,821.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.89% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of Shattuck Labs in a report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Shattuck Labs in a research note on Thursday.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.